|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 1 (January 1), 1999:
pp. 278-283
Arsenic Trioxide and Interferon- Synergize to Induce Cell Cycle
Arrest and Apoptosis in Human T-Cell Lymphotropic Virus Type
I-Transformed Cells
Ali Bazarbachi,
Marwan E. El-Sabban,
Rihab Nasr,
Frédérique Quignon,
Christian Awaraji,
Joelle Kersual,
Laurent Dianoux,
Yael Zermati,
Joud H. Haidar,
Olivier Hermine, and
Hughes de Thé
From the Departments of Internal Medicine and Biochemsitry, Human
Morphology, and Pathology and Laboratory Medicine, American University
of Beirut, Beirut, Lebanon; UPR 9051 CNRS, (Laboratoire associé
au comité de Paris de la Ligue contre le Cancer), Paris, France;
and CNRS URA 1461 and the Department of Hematology, Necker Hospital,
Paris, France.
Human T-cell lymphotropic virus type I (HTLV-I) is the causative
agent of adult T-cell leukemia/lymphoma (ATL). ATL is an aggressive
proliferation of mature activated T cells associated with a poor
prognosis. The combination of the antiviral agents, zidovudine (AZT)
and  interferon (IFN), is a potent treatment of ATL. Recently,
arsenic trioxide (As) was shown to be an effective treatment of acute
promyelocytic leukemia (APL). We have tested the effects of the
combination of As and IFN on cell proliferation, cell cycle phases
distribution, and apoptosis in ATL-derived or control T-cell lines. A
high synergistic effect between IFN and As was observed in ATL-derived
cell lines in comparison to the control cell lines, with a dramatic
inhibition of cell proliferation, G1 arrest, and induction of
apoptosis. Similar results were obtained with fresh leukemia cells
derived from an ATL patient. Although the mechanisms involved are
unclear, these results could provide a rational basis for combined As
and IFN treatments in ATL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Kchour, M. Tarhini, M.-M. Kooshyar, H. El Hajj, E. Wattel, M. Mahmoudi, H. Hatoum, H. Rahimi, M. Maleki, H. Rafatpanah, et al.
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)
Blood,
June 25, 2009;
113(26):
6528 - 6532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tsukasaki, O. Hermine, A. Bazarbachi, L. Ratner, J. C. Ramos, W. Harrington Jr, D. O'Mahony, J. E. Janik, A. L. Bittencourt, G. P. Taylor, et al.
Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting
J. Clin. Oncol.,
January 20, 2009;
27(3):
453 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Dbaibo, Y. Kfoury, N. Darwiche, S. Panjarian, L. Kozhaya, R. Nasr, M. Abdallah, O. Hermine, M. El-Sabban, H. de The, et al.
Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity
Haematologica,
June 1, 2007;
92(6):
753 - 762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ishitsuka, J. Suzumiya, M. Aoki, K. Ogata, S. Hara, and K. Tamura
Therapeutic potential of arsenic trioxide with or without interferon-{alpha} for relapsed/refractory adult T-cell leukemia/lymphoma
Haematologica,
May 1, 2007;
92(5):
719 - 720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Brown, M. Bellon, and C. Nicot
Emodin and DHA potently increase arsenic trioxide interferon-{alpha}-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1
Blood,
February 15, 2007;
109(4):
1653 - 1659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chen, R. Chan, S. Waxman, and Y. Jing
Buthionine Sulfoximine Enhancement of Arsenic Trioxide-Induced Apoptosis in Leukemia and Lymphoma Cells Is Mediated via Activation of c-Jun NH2-Terminal Kinase and Up-regulation of Death Receptors
Cancer Res.,
December 1, 2006;
66(23):
11416 - 11423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-F. Che, C.-L. Zheng, S. Owatari, M. Mutoh, T. Gotanda, H.-C. Jeung, T. Furukawa, R. Ikeda, M. Yamamoto, M. Haraguchi, et al.
Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines
Blood,
June 15, 2006;
107(12):
4880 - 4887.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen
T-cell non-Hodgkin lymphoma
Blood,
February 15, 2006;
107(4):
1255 - 1264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Diaz, M. Colombo, K. K. Mann, H. Su, K. N. Smith, D. S. Bohle, H. M. Schipper, and W. H. Miller Jr
Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines
Blood,
February 1, 2005;
105(3):
1237 - 1245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. C. Moura, Y. Lepelletier, B. Arnulf, P. England, C. Baude, C. Beaumont, A. Bazarbachi, M. Benhamou, R. C. Monteiro, and O. Hermine
A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients
Blood,
March 1, 2004;
103(5):
1838 - 1845.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Feng, N. Vander Heyden, and L. Ratner
Alpha Interferon Inhibits Human T-Cell Leukemia Virus Type 1 Assembly by Preventing Gag Interaction with Rafts
J. Virol.,
December 15, 2003;
77(24):
13389 - 13395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mohapatra, B. Chu, S. Wei, J. Djeu, P. K. Epling-Burnette, T. Loughran, R. Jove, and W. J. Pledger
Roscovitine Inhibits STAT5 Activity and Induces Apoptosis in the Human Leukemia Virus Type 1-Transformed Cell Line MT-2
Cancer Res.,
December 1, 2003;
63(23):
8523 - 8530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. McCafferty-Grad, N. J. Bahlis, N. Krett, T. M. Aguilar, I. Reis, K. P. Lee, and L. H. Boise
Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells
Mol. Cancer Ther.,
November 1, 2003;
2(11):
1155 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mathas, A. Lietz, M. Janz, M. Hinz, F. Jundt, C. Scheidereit, K. Bommert, and B. Dorken
Inhibition of NF-{kappa}B essentially contributes to arsenic-induced apoptosis
Blood,
August 1, 2003;
102(3):
1028 - 1034.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sturlan, M. Baumgartner, E. Roth, and T. Bachleitner-Hofmann
Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells
Blood,
June 15, 2003;
101(12):
4990 - 4997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nasr, A. Rosenwald, M. E. El-Sabban, B. Arnulf, P. Zalloua, Y. Lepelletier, F. Bex, O. Hermine, L. Staudt, H. de The, et al.
Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells
Blood,
June 1, 2003;
101(11):
4576 - 4582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman
Mechanisms of Action of Arsenic Trioxide
Cancer Res.,
July 15, 2002;
62(14):
3893 - 3903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mahieux, C. Pise-Masison, A. Gessain, John. N. Brady, R. Olivier, E. Perret, T. Misteli, and C. Nicot
Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage
Blood,
December 15, 2001;
98(13):
3762 - 3769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sordet, C. Rebe, I. Leroy, J.-M. Bruey, C. Garrido, C. Miguet, G. Lizard, S. Plenchette, L. Corcos, and E. Solary
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis
Blood,
June 15, 2001;
97(12):
3931 - 3940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Murgo
Clinical Trials of Arsenic Trioxide in Hematologic and Solid Tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies
Oncologist,
April 1, 2001;
6(90002):
22 - 28.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. J. McCabe Jr., K. P. Singh, S. A. Reddy, B. Chelladurai, J. G. Pounds, J. J. Reiners Jr., and J. C. States
Sensitivity of Myelomonocytic Leukemia Cells to Arsenite-Induced Cell Cycle Disruption, Apoptosis, and Enhanced Differentiation Is Dependent on the Inter-Relationship between Arsenic Concentration, Duration of Treatment, and Cell Cycle Phase
J. Pharmacol. Exp. Ther.,
November 1, 2000;
295(2):
724 - 733.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. E. El-Sabban, R. Nasr, G. Dbaibo, O. Hermine, N. Abboushi, F. Quignon, J. C. Ameisen, F. Bex, H. de The, and A. Bazarbachi
Arsenic-interferon-alpha -triggered apoptosis in HTLV-I transformed cells is associated with Tax down-regulation and reversal of NF-kappa B activation
Blood,
October 15, 2000;
96(8):
2849 - 2855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Rego, L.-Z. He, R. P. Warrell Jr., Z.-G. Wang, and P. P. Pandolfi
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
PNAS,
August 17, 2000;
(2000)
180290497.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. J. Roboz, S. Dias, G. Lam, W. J. Lane, S. L. Soignet, R. P. Warrell Jr, and S. Rafii
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
Blood,
August 15, 2000;
96(4):
1525 - 1530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Costantini, E. Jacotot, D. Decaudin, and G. Kroemer
Mitochondrion as a Novel Target of Anticancer Chemotherapy
J Natl Cancer Inst,
July 5, 2000;
92(13):
1042 - 1053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nicot, R. Mahieux, S. Takemoto, and G. Franchini
Bcl-XL is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples
Blood,
July 1, 2000;
96(1):
275 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Perkins, C. N. Kim, G. Fang, and K. N. Bhalla
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL
Blood,
February 1, 2000;
95(3):
1014 - 1022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Kroemer and H. de The
Arsenic Trioxide, a Novel Mitochondriotoxic Anticancer Agent?
J Natl Cancer Inst,
May 5, 1999;
91(9):
743 - 745.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Rego, L.-Z. He, R. P. Warrell Jr., Z.-G. Wang, and P. P. Pandolfi
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
PNAS,
August 29, 2000;
97(18):
10173 - 10178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
